One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...

A nasal spray would be a workaround for drug resistance seen with oral diuretics, with the potential to reduce hospital ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO, IL—For patients with a history of acute MI who are vulnerable to the cardiovascular risks posed by influenza ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.